Disease Modifying Treatment (Dmt) is Associated with Lower Hazard for Death Among Multiple Sclerosis (Ms) Patients: Survival Analysis Based on 30 Years Incident Ms Cohort

Abstract

A427for one year prior to the index date (baseline) and one subsequent year after the index date (follow-up). Relapses were recorded for all patients during the followup. Results: After matching, there were 177 patients in the Switch group and 531 in the No Switch group. Baseline characteristics were well matched between groups (47 years old; 79% female). The proportion of patients experiencing a relapse during the follow-up year was significantly higher in the Switch group compared with the No Switch group (13.6%vs. 6.2%, p= 0.002). Annual relapse rate was significantly higher in the Switch group compared with the No Switch group (0.15 vs. 0.07, p= 0.002). ConClusions: MS patients stable on interferon therapy who remain on initial therapy had significantly better outcomes, as measured by less than half the proportion of patients with relapses and half the annual relapse rate, than patients who switched to another interferon. This supports the benefits of allowing patients to remain on current interferon therapy when stable. PND14PharmacotheraPies for the treatmeNt of Behavioral aND Psychological symPtoms of DemeNtia -a systematic review oN receNt eviDeNce